Early Innovation Awards

As a company committed to therapeutic progress to serve patient needs, Servier takes an open and collaborative approach to R&D at every stage of the drug development life cycle, including early-stage discovery – where we are proud to support the next generation of innovation.

Our awards recognize the aspiring life-science companies and entrepreneurs who are driving scientific innovation in areas of high unmet need, including hard-to-treat diseases in oncology, neuroscience and immuno-inflammation, as well as those pursuing research in translational medicine, drug development technologies and drug delivery platforms.

Golden Tickets:
Cambridge, MA


Servier is a proud Gold sponsor of LabCentral, a premier shared laboratory space located in Cambridge, Massachusetts, designed as a launchpad for life science and biotech startups. Each year, Servier sponsors a contest to award one “Golden Ticket” to support and celebrate promising life-science companies and entrepreneurs. The winner of the “Golden Ticket” will receive a $50,000 credit towards space and services available at LabCentral 700 for use within a 13-month period. Servier will also provide access to its team of talented experts who can provide guidance and feedback to early-stage companies.



2023 Servier Golden Ticket Contest: LabCentral

Servier is pleased to open the call for applications for the 2023 Golden Ticket Contest to interested startups developing innovative approaches in the following discovery and early clinical areas of interest:

  • Innovative therapeutic approaches in: 
    • Oncology: Cancer cell targeting (e.g., synthetic lethality, precision oncology) and immuno-oncology (e.g., tumor micro-environment, T-cell targeting)
    • Neuroscience: Rare neurological disorders (e.g., Familial Amyotrophic Lateral Sclerosis, genetically driven pediatric epilepsies) and sub-populations of neurodegenerative diseases
    • Immuno-inflammation: Autoantibody-driven autoimmune diseases and related conditions with similar pathophysiological mechanisms
  • Novel modality development strategies for small molecules, biologics (including bi-specifics, ADCs) and oligonucleotides (including ASOs), as well as targeted delivery strategies (e.g., tumor-specific, CNS delivery mechanisms)
  • AI/ML data-driven platforms for drug design (including oligonucleotides and antibodies) and to support translational activities (target and biomarker identification) 

How to Apply:

To apply, submit a non-confidential pitch deck highlighting your innovative approach to advancing therapies for patients with high unmet needs to: GoldenTicket@servier.com. All submissions will be reviewed. Three semi-finalists will be invited to a pitch event at LabCentral in Cambridge, MA, where the Golden Ticket winner will be announced!


  • Application submission deadline: March 10, 2023
  • Submission review: March 13 – April 3, 2023
  • Golden Ticket semi-finalists notified: April 3, 2023
  • Servier Golden Ticket pitch event and announcement of finalist: April 12, 2023


The winner of the “Golden Ticket” Contest shall receive a $50,000 credit towards space and services available at LabCentral 700 for use within a 13-month period, beginning upon receipt. Additional terms and conditions apply, subject to Servier and LabCentral’s discretion. All submissions shall be reviewed. Recipient shall not receive consideration in the form of cash. Recipients seeking access to, and discussions with, Servier employees in the form of guidance or feedback may be required to execute appropriate confidentiality agreements, at Servier’s discretion.

Any questions or comments regarding this contest can be directed to: GoldenTicket@servier.com


Servier as a Partner-of-Choice

  • Independent, ensuring continuity and long-term perspective in partnerships
  • Committed to serving patient needs by working with patients at all stages of the drug development life cycle 
  • Global geographical footprint, with a presence in both established and emerging markets
  • Science driven and substantial R&D investment designed to build a high-quality and sustainable portfolio 
  • Strong capabilities from research to commercialization
  • Over 70 active global partnerships across pharma, biotech and academia

More from Servier


Our partnership are a core part of our business. We are seeking partners who share our values and commitment to improving the lives of patients, caregivers and families we serve.

Learn More

About Us

Servier Pharmaceuticals is a privately held pharmaceutical company focused on Oncology. Everything we do is to bring the promise of tomorrow to the patients we serve.

Learn More

Research & Development

We invest in innovative research and development through our own development or partnerships to best address the unmet needs of patients.

Learn More